DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Endroit courant :
> This Story

Ouverture ou Registre to rate this News Story
Forward Printable StoryPrint Comment



Molecular Imaging Homepage

PET tracer may help assess promising Alzheimer's treatment Visualizing progress with 18F-AV45 PET imaging agent

New nanoparticle technology may replace MR for cancer detection Shows promise in preclinical study

US Nuclear Corp signs letter of intent to manufacture MIFTEC medical isotope generators Utilizes MIFTI's Staged Z-Pinch fusion technique

The five most important questions to ask about SPECT service Insights from Craig Snodgrass, national service manager at Universal Medical

Cerveau signs research contract with UV Medical Center in Amsterdam For the manufacture and supply of PET agent MK-6240

Expert makes the case for patient access to radiology reports Patients want a more active role in their care

Global PET/CT scanner market projected to reach $2.1 billion by 2023 Growth spurred in part by increased Medicare coverage

Can theranostics be the key to completely curing colorectal cancer? Preclinical trials yield promising results

Cerveau Technologies to collaborate in development of PET imaging agents for Alzheimer’s disease

MJFF and Tau Consortium partner to accelerate the development of new PET tracers May detect early stage neurodegenerative disease

Made of the vital element manganese

MGH team develops a potential alternative to gadolinium-based contrast agents

par Lauren Dubinsky , Senior Reporter
A team at Massachusetts General Hospital developed an MR imaging agent that may be used as an alternative to gadolinium-based contrast agents.

In recent years there have been concerns over the health risks associated with gadolinium for certain patients, and the industry has been searching for safer options.

Story Continues Below Advertisement

CT, MRI, NM, SPECT/CT, PET & PET/CT service, refurbished systems and parts

Accelerate your ROI with our Black Diamond Certified refurbished systems. One year warranty - ISO 13485 Certified - FDA registered - Over 65k parts in inventory

"There is a clear clinical need for gadolinium-free MR contrast agents," Peter Caravan, co-director of the Institute for Innovation in Imaging at MGH, told HCB News. "This is most apparent for patients with renal impairment, for whom GBCAs pose the risk of potentially devastating nephrogenic systemic fibrosis."

Caravan and his team developed a manganese-based agent called Mn-PyC3A. It can produce an MR signal comparable to that of GBCAs, and manganese is an essential element that the human body requires in small amounts.

The body naturally excretes excess manganese, but any gadolinium that is released from GBCAs is likely be retained in the body indefinitely. Studies have shown that it remains in the brain years after it was administered to the patient.

"The challenge with using manganese is being able to bind it tightly so that it is not released in the body, and to do this in a way that the strong MR signal remains," said Caravan. "Mn-PyC3A meets these requirements. Mn-PyC3A doesn't bind or interact with proteins or enzymes in the body, suggesting that its risk of causing adverse side effects is lower."

The team previously conducted mouse experiments and found that Mn-PyC3A provided good enhancement of blood vessels, liver and kidneys, and over 99 percent was excreted from the body within 24 hours by the liver and kidney.

In a more recent study published in Radiology, they compared the use of Mn-PyC3A to a commonly used GBCA in a baboon model. Each animal underwent two MR exams — one with Mn-PyC3A and one with the GBCA.

Once again, they found that the kidney and liver quickly excreted Mn-PyC3A and there was no evidence of the release of free manganese.

"Our MR contrast agent could replace GBCAs," said Caravan. "Mn-PyC3A was designed as a direct substitute for GBCAs, providing the same imaging results as GBCAs when used for the same disease indications. There are a number of studies that are needed for this replacement to happen."

They need to follow the FDA-mandated path to regulatory approval, which includes completing pre-clinical safety studies. Then they need to show in clinical trials that Mn-PyC3A is safe and provides the requisite diagnostic information.

"Once radiologists and referring physicians have experience showing that Mn-PyC3A provides the same diagnostic information as GBCAs and is safe to use, we think there will be widespread adoption of Mn-PyC3A," said Caravan.

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment

Développez la notoriété de votre marque
Enchères + Ventes Privées
Obtenir le meilleur prix
Acheter des équipement / pièces
Trouver le meilleur prix
Infos du jour
Lire Les dernières nouvelles
Consulter tous les utilisateurs DOTmed
Éthique concernant DOTmed
Voir notre programme d'éthique
L'or partie le programme de fournisseur
Recevoir des demandes PH
Programme de marchand de service d'or
Recevoir des demandes
Fournisseurs de soins de santé
Voir tous les outils des HCP (abréviation pour les professionnels de la santé)
Les travaux/Formation
Trouver / combler un poste
Parts Hunter +EasyPay
Obtenir des devis de pièces
Certification Récentes
Voir les utilisateurs récemment certifiés
Evaluation Récentes
Voir les utilisateurs récemment certifiés
Central de location
Louer de l’équipement à moindre prix
Vendre des équipements / pièces
Obtenir le maximum d'argent
Service le forum de techniciens
Trouver de l'aide et des conseils
Simple demande de propositions
Obtenir des devis pour des appareils
Expo Virtuelle
Trouver des services d'appareils
L'Access et l'utilisation de cet emplacement est sujet aux modalités et aux conditions du notre de nos MENTIONS LEGALES & DONNEES PERSONELLES
Propriété de et classe des propriétaires DOTmedà .com, inc. Copyright ©2001-2017, Inc.